title: Inhibition of key digestive enzymes related to diabetes and hyperlipidemia and protection of liver-kidney functions by trigonelline in diabetic rats.
abstract: Diabetes is a serious health problem and a source of risk for numerous severe complications such as obesity and hypertension. Treatment of diabetes and its related diseases can be achieved by inhibiting key digestive enzymes related to starch and lipid digestion. The findings revealed that the administration of trigonelline to surviving diabetic rats helped to protect the pancreas β-cells from death and damage. Additionally, the supplement of trigonelline to surviving diabetic rats significantly decreased intestinal α-amylase and maltase by 36 and 52%, respectively, which led to a significant decrease in the blood glucose rate by 46%. Moreover, the administration of trigonelline to surviving diabetic rats potentially inhibited key enzymes of lipid metabolism and absorption such as lipase activity in the small intestine by 56%, which led to a notable decrease in serum triglyceride (TG) and total cholesterol (TC) rates and an increase in the HDL cholesterol level. This treatment also improved glucose, maltase, starch, and lipid oral tolerance. Trigonelline was also observed to protect the liver-kidney functions efficiently, which was evidenced by the significant decrease in the serum aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), and lactate dehydrogenase (LDH) activities and creatinine, albumin, and urea rates. The histological analysis of the pancreas, liver, and kidney tissues further established the positive effect of trigonelline. Overall, the findings presented in this study demonstrate that the administration of trigonelline to diabetic rats can make it a potentially strong candidate for industrial application as a pharmacological agent for the treatment of hyperglycemia, hyperlipidemia, and liver-kidney dysfunctions.
authors: Biotechnology High School of Sfax (ISBS),University of Sfax, Soukra Km 45; PO Box 261, Sfax 3038, Tunisia.
authors: Khaled
authors: K
authors: Hamden
authors: Kais
authors: K
authors: Mnafgui
authors: Zahra
authors: Z
authors: Amri
authors: Ahmed
authors: A
authors: Aloulou
authors: Abdelfattah
authors: A
authors: Elfeki
keywords: Diabetes; Digestive enzymes; Lipase; Pancreas; Trigonelline
references: Lancet. 2011 Jul 2;378(9785):31-40
references: 21705069
references: PLoS One. 2012;7(6):e39773
references: 22745826
references: Bioresour Technol. 2010 Jun;101(12):4676-89
references: 20185303
references: BMC Complement Altern Med. 2012 May 16;12:63
references: 22591682
references: Diabetes Care. 2009 Jun;32(6):1023-5
references: 19324944
references: Indian J Exp Biol. 2010 Nov;48(11):1111-8
references: 21117451
references: Biochem Pharmacol. 2011 Dec 15;82(12):1963-70
references: 21946084
references: Lipids Health Dis. 2011 Dec 05;10:226
references: 22142357
references: J Agric Food Chem. 2005 Jun 1;53(11):4593-8
references: 15913331
references: Altern Med Rev. 2003 Feb;8(1):20-7
references: 12611558
references: Sci Pharm. 2011;79(4):951-61
references: 22145117
references: Curr Med Chem. 2012;19(21):3523-31
references: 22680628
references: Indian J Clin Biochem. 2012 Jan;27(1):21-7
references: 23277708
references: Indian J Exp Biol. 2010 Nov;48(11):1119-22
references: 21117452
references: Indian J Clin Biochem. 2011 Oct;26(4):335-46
references: 23024468
references: Expert Opin Ther Targets. 2012 Mar;16(3):269-97
references: 22360606